


Hepatitis C: State of Medicaid Access Report Card

Oklahoma



Grade	Recommendations to Improve Patient Access
A+	<ul style="list-style-type: none"> Continue to ensure broad access to HCV treatment.

State Overview

As of October 2023, 1,087,062 individuals were enrolled in Medicaid and CHIP.¹ It is estimated that as of 2016, 53,300 people were living with HCV in Oklahoma.² Oklahoma Medicaid does not contract with any managed care organizations (MCOs).

The Oklahoma Medicaid Preferred Drug List designates Mavyret as the preferred agent.³

Deductions		Policy
Prior Authorization		Prior authorization is not required for the preferred agent (Mavyret). ⁴ “Initial PA requests for all other direct-acting antivirals besides Mavyret must be submitted using 3 PA forms: 1. The medication-specific form, 2. Hepatitis C Therapy Intent to Treat Contract form (Pharm-28) and 3. Hepatitis C Therapy Pharmacy Agreement form (Pharm-29). Continuation requests (for each refill) must be submitted using the Hepatitis C Therapy Continuation form (Pharm-30).” ⁵
Fibrosis Restrictions		Oklahoma Medicaid does not impose fibrosis restrictions. ⁶
Substance Use Restrictions		Oklahoma Medicaid does not impose substance use restrictions for the preferred agent. ⁷
Prescriber Restrictions		Oklahoma Medicaid does not impose prescriber restrictions. ⁸
Retreatment Restrictions		Oklahoma Medicaid does not impose retreatment restrictions. ⁹
Access in Managed Care		Oklahoma does not contract with MCOs. ¹⁰
Additional Restrictions		Oklahoma Medicaid does not impose additional restrictions for the preferred agent. ¹¹
Total Deductions	Total Score [100-Deductions]	Grade
-0	100	A+

Contact Your State Officials

Medicaid Office¹²: Traylor Rains, Medicaid Director, Oklahoma Health Care Authority, State of Oklahoma
4345 North Lincoln Blvd., Oklahoma City, OK 73105; Telephone: (405) 522-7365, Traylor.rains@okcha.org

Key Sources

Clinical Criteria: [Oklahoma Health Care Authority, Hepatitis Disorders: Hepatitis C Criteria \(Jul. 28, 2022\)](#).

Prior Authorization Forms (for Non-Preferred Agents): [OHCA, Hepatitis Disorders: Hepatitis C Prior Authorization Forms \(Jul. 28, 2022\)](#).

Hepatitis C Therapy Intent to Treat Contract (for Non-Preferred Agents): [OHCA, Hepatitis C Therapy Intent to Treat Contract \(Dec. 30, 2021\)](#).

Hepatitis C Therapy Pharmacy Agreement Form (for Non-Preferred Agents): [OHCA, Hepatitis C Therapy Pharmacy Agreement \(Dec. 30, 2021\)](#)

Hepatitis C Therapy Continuation Form (for Non-Preferred Agents): [OHCA, Hepatitis C Continuation Form \(Jun. 18, 2014\)](#)

-
- ¹ Centers for Medicare & Medicaid Services, Medicaid & CHIP in Oklahoma, <https://perma.cc/Q8PC-F2KZ>.
 - ² HepVu, Local Data: Oklahoma State Profile, <https://perma.cc/D8WT-FWWG>.
 - ³ Clinical Criteria.
 - ⁴ Clinical Criteria.
 - ⁵ Oklahoma Health Care Authority, Mavyret (Glecaprevir/Pibrentasvir) Update Letter (Aug. 29, 2022), <https://perma.cc/UL3M-U7D9>.
 - ⁶ Clinical Criteria.
 - ⁷ Clinical Criteria.
 - ⁸ Clinical Criteria.
 - ⁹ Clinical Criteria.
 - ¹⁰ Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems (Jul. 1, 2022), <https://perma.cc/EMN8-QR8B>.
 - ¹¹ Clinical Criteria.
 - ¹² National Association of Medicaid Directors, Medicaid Directors, <https://perma.cc/RK6K-TFKK>.